xi's moments
Home | Companies

30 years on, AstraZeneca sees healthy future

By CANG WEI | chinadaily.com.cn | Updated: 2023-05-24 19:53

AstraZeneca's Global R&D China Center in Shanghai. [Photo provided to chinadaily.com.cn]

AstraZeneca has introduced nearly 40 innovative medicines to China, with another 15 expected to be available in the country by 2030.

As early as 2001, the biopharmaceutical company saw the huge potential of China in manufacturing and invested over $100 million in building a supply base in Wuxi, which was then AstraZeneca's largest facility in Asia.

Wuxi is now a strategic city for AstraZeneca, as it features headquarters functions in production, management, R&D, innovation, capital and talent.

Global Edition
BACK TO THE TOP
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349